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ferences between responders in the treatment groups pro-
vides a more comprehensive characterization of the
treatment effect.
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BACKGROUND: Economic aspects are important when
assessing the overall benefit of a treatment strategy. The
number of investigations of these aspects are few within
the field of Crohn’s disease (CD). OBJECTIVE: To assess
the economic consequences, from a health care budget
perspective, of treating CD patients with budesonide CIR
(Entocort capsules) 6 mg per day as maintenance therapy
compared to no maintenance treatment (NMT). METHOD:
A validated decision-analytic model (Noble et al., 1998)
on the treatment of CD in Sweden was used. The model
used pooled patient data from randomised, double blind
trials of budesonide CIR capsules (n  90) versus placebo
(n  90) and covers a study period of one year. For
events not investigated in the clinical trials, literature and
panel data were used. Cost inputs for health care re-
sources were based on costs observed for 11 regional hos-
pitals in Sweden in year 1996. The analysis took into ac-
count costs for health care resources associated with
managing inactive and active phases of CD, e.g., diagnos-
tic and surgical procedures, physician visits, hospitalisa-
tions and drug consumption. Panel data and cost inputs
were tested in a sensitivity analysis. RESULT: Average
annual cost per patient was SEK 36,745 for budesonide
CIR capsules patients compared to SEK 38,130 for NMT
patients. With a Swedish prevalence between 13,000 to
18,000 patients this could mean annual savings of 18 to
25 million SEK (2–2.8 million USD). Stability of the re-
sults was confirmed when altering values on panel data
and cost inputs. CONCLUSION: Budesonide CIR capsules,
prolonging time in remission, is a cost-saving treatment
strategy for the treatment of Crohn’s disease in Sweden.
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OBJECTIVES: Helicobacter pylori (H.pylori) eradication
triple therapy with a combination of lansoprazole, amox-
icillin, and clarithromycin was approved in September
2000 in Japan. The objective of this analysis was to com-
pare the cost-effectiveness of this eradication therapy
with conventional H2RA therapy in Japan. METHODS:
We used decision analysis software to establish two
Markov models, one for gastric ulcers and the other for
duodenal ulcers. The model design was based on the Jap-
anese H. pylori eradication guideline and specialists opin-
ions. The model input data were derived mainly from a
literature review. The models predict the direct medical
costs, number of disease free days (DFDs) and cost per
DFD for five years. Sensitivity analyses were conducted
by varying the success rate and the probability of endo-
scopic relapse in symptomatic patients. The payer’s per-
spective was selected. RESULTS: According to the gastric
ulcer model, the expected total costs of eradication and
conventional therapies for an individual patient at the
end of five years would be 169,719 Yen and 390,921
Yen, respectively; the expected DFDs 1,454 days and
1,313 days, respectively; and the expected cost per DFD
117 Yen and 298 Yen, respectively. According to the
duodenal ulcer model, the expected total costs of the
eradication and conventional therapies would be 134,786
Yen and 324,689 Yen, respectively; the expected DFDs
1,503 days and 1,387 days, respectively; and the ex-
pected cost per DFD 90 Yen and 234 Yen, respectively.
The sensitivity analyses showed the results of baseline
analysis to be robust. CONCLUSIONS: We found that
this eradication therapy is less costly and more effective
than conventional therapy for the treatment of gastric
and duodenal ulcers in a Japanese medical setting. Thus,
eradication therapy is recommended for gastric and
duodenal ulcers from an economic as well as a clinical
viewpoint, in Japan.
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OBJECTIVE: To assess the economic outcome, from a
health care budget perspective, of treating Crohn’s dis-
ease (CD) patients with budesonide controlled ileal re-
lease (CIR) 6 mg per day as maintenance therapy com-
pared to no maintenance therapy (NMT). METHODS: A
validated decision-analytic model (Noble et al., 1998) on
the treatment of (CD) was used. The model was adjusted
to specifically depict CD patient management in Finland.
The analysis was based on pooled patient data from ran-
domised, double blind clinical trials comparing budes-
onide CIR (n  90) in maintenance therapy with placebo
(n  90). In accordance with the clinical trials the analy-
sis covered a study period of up to one year. The analysis
took into account clinical outcomes and consequences of
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these in terms of health care resource use and associated
costs, e.g., costs of hospitalisations, diagnostic and surgi-
cal procedures, outpatient care and drug consumption.
Panel and literature data was used for events not investi-
gated in the clinical trials. Cost inputs were derived from
Tampere University Hospital for year 1998. Days in re-
mission and relapse were translated into Quality Ad-
justed Life Years (QALYs) using CD specific health-state
utility data from the literature. RESULTS: The outcomes
of the clinical trials were reflected in the model as a
26.4% reduction in annual number of relapses for the av-
erage patient in the budesonide CIR treatment group.
Mean annual health care cost per patient was 17,740
FIM (2,000 USD) for the budesonide CIR patient and
16,608 FIM (1,877 USD) for the NMT patient. The dif-
ference between the groups amounted to a cost per
gained QALY of 68,610 FIM (7,753 USD), which is well
in line with what is considered a cost-effective treatment
strategy. CONCLUSION: Budesonide CIR means fewer
relapses per average patient and is a cost-effective treat-
ment strategy for the treatment of Crohn’s disease in Fin-
land.
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OBJECTIVES: Gastroesophageal reflux disease (GERD)
is a common condition associated with a variety of symp-
toms, particularly heartburn. The purpose of this study
was to assess patient-reported symptom distress in a ran-
domized trial of rabeprazole (RAB), a proton pump in-
hibitor. METHODS: Symptom distress was measured us-
ing the Distress subscale of the GERD Symptom Assessment
Scale (GSAS) that asks patients about the degree of
bother they experience for 15 symptoms. Patients com-
pleted the GSAS at baseline and week 4. We evaluated
the impact of treatment (RAB 10mg, RAB 20mg, or pla-
cebo) on mean change in GSAS Distress scores using an
ANCOVA model. We also conducted a relative variabil-
ity analysis using ANOVA models to determine which of
5 clinical indicators are most useful to explain changes in
GSAS Distress scores. Mean change was assessed as a
function of baseline daytime heartburn severity, baseline
nighttime heartburn severity, time to first 24 hours with-
out heartburn symptoms, complete daytime heartburn re-
lief, and complete nighttime heartburn relief. RESULTS:
The sample consisted of 169 patients (RAB10mg  55,
RAB 20mg  56, placebo  58). Overall, a significant
difference in mean change in GSAS Distress scores was
observed across treatment groups (p  0.0007). Both the
RAB 10mg and RAB 20mg groups reported significantly
greater improvements in GSAS Distress scores than the
placebo group (p  0.0036 and p  0.0004, respectively).
Of the 5 clinical indicators examined, time to first 24
hours without heartburn explained the greatest amount
of variability in GSAS Distress scores. Achieving com-
plete daytime and complete nighttime heartburn relief
also were significant factors. CONCLUSIONS: In clinical
studies, RAB provided fast and consistent (both daytime
and nighttime) heartburn relief. Given that speed of
heartburn relief as well as achieving complete heartburn
relief were significant factors explaining variability in pa-
tient-reported symptom distress, the positive impact of
RAB on the GSAS distress scale was consistent with its
clinical efficacy.
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OBJECTIVES: With recent recognition of the primary
role of Helicobacter pylori (HP) in peptic ulcer disease, it
has been proposed that patients with dyspepsia undergo
noninvasive testing for HP, instead of endoscopy, fol-
lowed by antibiotics if positive. We evaluated cost-effec-
tiveness of ‘Test&Treat’ strategy versus empirical treat-
ment for HP infection in dyspeptic patients presenting in
the primary care setting. METHODS: The study was a
one-year incremental cost (yr2000 US dollars) per qual-
ity-adjusted life year (QALY) model for dyspeptic pa-
tients age less than 45 years old in a primary care setting
from a societal perspective. With ‘Test&Treat’ algo-
rithm, patients were tested for HP infection using urea
breath test. If positive, eradication was prescribed. Alter-
natively, patients were given conventional treatment of
H2RA for four weeks. If not cured, HP would be eradi-
cated empirically. Both direct and indirect costs were in-
cluded. The model took into consideration preventing
gastric cancer from eradication. Sensitivity analyses were
performed on prevalence of HP infection, drug treatment
efficacy, laboratory test costs, drug treatment costs, and
drug treatment utility loss. RESULTS: At baseline, with
HP prevalence of 40% and HP antibiotic eradication effi-
cacy of 89%, results showed that ‘Test&Treat’ had an in-
cremental cost-effective ratio (ICER) of $31,723/QALY.
One-way sensitivity analysis showed that antibiotic treat-
ment efficacies lower than 45–46% would exceed the so-
cietal threshold ICER of $50,000. CONCLUSIONS: The
model showed that ‘Test&Treat’ was cost-effective for
uncomplicated dyspeptic patients in primary care. Al-
though NIH guidelines state that all ulcer patients with
HP infection require eradication regimen, universal endo-
scopic diagnosis of ulcer causation (HP/HP) would not
be cost-effective. However, treating all patients empirically
could increase antibiotic resistance. The ‘Test&Treat’
strategy has the benefits of slowing antibiotic resistance
while avoiding high endoscopy costs. The model was ro-
